Telesis Bio Inc. announced continued expansion of the BioXp Select product line, releasing two novel kits to enable DNA amplification and scale-up. The BioXp Select DNA Cloning and Amplification Kit and the BioXp Select Plasmid Amplification Kit enable on-demand and automated synthesis and amplification of transfection-scale DNA beginning from the customers own DNA fragments or plasmid DNA, overnight and at the push of a button. This is expected to enable researchers to optimize their discovery workflows by reducing the time and steps for cloning and scale-up of DNA required for their testing and analysis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.7 USD | -0.27% | -2.37% | -48.48% |
05-09 | Earnings Flash (TBIO) TELESIS BIO Reports Q1 Revenue $3.4M | MT |
05-09 | Telesis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.48% | 6.23M | |
+4.85% | 212B | |
+9.86% | 188B | |
+31.11% | 157B | |
+34.08% | 114B | |
+3.42% | 64.01B | |
+19.45% | 54.88B | |
+1.63% | 48.83B | |
-3.12% | 39.3B | |
+1.93% | 35.97B |
- Stock Market
- Equities
- TBIO Stock
- News Telesis Bio, Inc.
- Telesis Bio Inc. Releases Bioxp® Select Kits to Enable DNA Amplification and Scale-Up